Galangin has been previously investigated in numerous studies and has exhibited anti-angiogenic and metastatic potential in liver cancer (HepG2) and ovarian cancer (OVCAR-3) cells, via suppression of the PKC/ERK and Akt/p70S6K/HIF-1α signaling pathways, respectively (Chien et al., 2015; Huang et al., 2015). The gene discussed is HIF1A; the disease is ovarian cancer.